BIVI Biovie Inc

P/E --
Forward P/E --
Price/Sales --
Beta 0.737
Div Yield --
Market Cap --

Company Analysis

Latest News

πŸ”΄ Biovie is trading 5% down today β€” no clear company-specific announcement identified

Biovie is trading 5.07% down at $1.97, with no clear company-specific announcement identified for September 9, 2026. - Recent catalyst remains anticipation of...

🟒 Biovie is trading 6.5% up today amid anticipation of ADDRESS-LC topline results

Biovie is trading 6.5% up at $2.13, possibly supported by anticipation of ADDRESS-LC topline results targeted before September 30, 2026. - Shares rose from...

🟒 Biovie is trading 6% up in pre-market with topline results expected by September's end

Biovie is trading 6% up at $2.12, based on its pre-market price versus the September 4, 2026 close of $2.00; the gain may reflect anticipation of upcoming...

πŸ”΄ Biovie is trading 10% down today despite broader market gains

Biovie is trading 10.04% down at $2.02, extending weakness despite biotechnology and major U.S. indexes moving higher on September 2, 2026; no company-specific...

πŸ”΄ Biovie is trading 6.47% down today β€” no company-specific explanation identified

Biovie is trading 6.47% down now at $2.10, despite broader biotechnology strength and higher major U.S. indexes; no company-specific announcement explaining...

🟒 Biovie is trading 6.14% up in pre-market after ending treatment in Phase 2 ADDRESS-LC trial

Biovie is trading 6.14% up at $2.42 after announcing on August 31, 2026, that treatment ended in its approximately 200-patient Phase 2 ADDRESS-LC trial of...

Biovie Insiders Put Their Own Money on the Line β€” But Can $49,000 in Purchases Signal Real Confidence in a $2 Stock?

Shares of Biovie Inc. (BIVI) jumped 11.6% to $2.41 on August 31 after SEC filings revealed that four company insiders β€” including the CEO β€” bought stock on the...

🟒 Biovie is trading 11.59% up today after four insiders bought shares

Biovie is trading 11.59% up at $2.41 after four insiders reported open-market purchases following the August 28 session. - CEO Cuong V. Do bought 15,210...

🟒 Biovie is trading 6.48% up in pre-market amid reported insider purchases

Biovie is trading at $2.30, up +6.48% in pre-market amid reported insider purchases. - Multiple insiders reported purchases after the August 28 session,...

πŸ”΄ Biovie is trading 5.21% down today amid unclear catalyst

Biovie is trading 5.21% down at $2.00, with no verified company-specific announcement identified on August 27, 2026, and the catalyst remains unclear. - Its...

πŸ”΄ Biovie is trading 5.21% down in pre-market; catalyst remains unclear

Biovie is trading 5.21% down at $1.98 in pre-market, with the catalyst unclear. - It closed at $2.09 on August 25, 2026. - Searches found no verified...

πŸ”΄ Biovie is trading 9.81% down today with no verified company-specific explanation

Biovie is trading 9.81% down at $1.93, with no verified company-specific announcement dated August 24 or August 25 explaining the decline. - The stock closed...

πŸ”΄ Biovie is trading 6.39% down in pre-market with no verified explanation for decline

Biovie is trading at $2.00, down 6.39% after closing at $2.14 on August 24, 2026; no verified announcement explains the decline. - No verified Biovie...

πŸ”΄ Biovie is trading 6.04% down today in after-hours trading as the immediate catalyst remains unclear

Biovie is trading 6.04% down at $2.01 after closing at $2.14 on August 24, 2026; the immediate catalyst remains unclear. - No verified company-specific...

🟒 Biovie is trading 7.69% up today with no clear catalyst identified

Biovie is trading 7.69% up at $2.10, with no clear catalyst identified for the move. - The stock is extending a highly volatile rebound after rising 38.81% on...

πŸ”΄ Biovie is trading 8.21% down today as Nasdaq falls 0.60%

Biovie is trading at $1.79 (-8.21%) during early August 24, 2026 trading amid broader risk-off pressure alongside a 0.60% Nasdaq loss. - The decline follows a...

πŸ”΄ Biovie is trading 6.15% down in pre-market

Biovie is trading at $1.83, down -6.15% in pre-market, with the immediate reason unclear. - No new company-specific announcement or earnings catalyst was...

🟒 Biovie is trading 25.38% up today after statistically significant Phase 2 SUNRISE-PD results

Biovie is trading 25.38% up at $2.33 after renewed investor attention to positive Phase 2 SUNRISE-PD results for bezisterim in early Parkinson’s disease. -...

🟒 Biovie is trading 11.38% up in pre-market after positive Phase 2 SUNRISE-PD results

Biovie is trading at $2.07, up 11.38% in pre-market after positive Phase 2 SUNRISE-PD results for bezisterim in early Parkinson’s disease. - The trial met its...

🟒 Biovie Inc is trading 6.45% up in pre-market

BIVI is trading at $1.98, up 6.45% in pre-market.